Ready to crush your New Year’s health goals? These breakthrough medications offer more than weight loss—they support your ...
Eli Lilly's dominance in the GLP-1 market and strong revenue growth forecast make LLY stock a promising investment, with a ...
Zepbound (tirzepatide) is reshaping the competitive landscape in obesity treatment, challenging Novo Nordisk A/S' (NYSE:NVO) ...
at a significantly lower cost — around $250 to $350 per month for tirzepatide, compared to Zepbound's list price of $1,059. With the official shortage over, the FDA has signaled it will crack ...
Eli Lilly and Novo Nordisk have been competing in the obesity market for the past year, making it an opportune time to review the benefits of the two most prominent obesity medications.
Cheaper versions of the drug, known as compounded tirzepatide, might be restricted in 2025. Patients could face higher costs and tougher access, and telehealth is racing to adapt. The FDA has ...
The weight loss medication tirzepatide (Mounjaro and Zepbound) is no longer in shortage, according to the FDA. Access to ...
Patients taking a compounded alternative to Eli Lilly's weight loss drug Zepbound will need to transition to the name-brand ...
Cheaper versions of the drug, known as compounded tirzepatide, might be restricted in 2025. Patients could face higher costs and tougher access, and telehealth is racing to adapt. The FDA has ...
Weight loss efficacy: While both medications are highly effective for weight loss, studies suggest tirzepatide may lead to greater reductions in body weight due to its dual-action mechanism. Cost ...
The U.S. Food and Drug Administration (FDA) recently approved Zepbound® (tirzepatide) as the first prescription medication for treating moderate-to-severe obstructive sleep apnea (OSA) in adults with ...